| Evaluation of Efficacy and Tolerability of Glimepiride and Metformin Combination: A Multicentric Study in Patients with Type-2 Diabetes Mellitus, Uncontrolled on Monotherapy with Sulfonylurea or Metformin. | |
| | |
MedLine Citation:
|
PMID: 21326082 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The objectives of this study were to evaluate the efficacy and tolerability of glimepiride plus extended release metformin (MET) on glycemic control in patients with type-2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or MET. This was a prospective, open-labeled, multicentric study over 12 weeks. Patients who were diagnosed with type-2 diabetes and were uncontrolled on monotherapy with single oral hypoglycemic agents such as glimepiride or MET and characterized by glycosylated hemoglobin (HbA1c) ≥7% and ≤10% and fasting plasma glucose (FPG) ≥ 140 mg/dL were enrolled in this study. Treatment regimen was started at 1 mg of glimepiride plus 500 mg of MET once a day and was titrated to next dose level depending on the clinician's judgment, not exceeding a total daily dose of 8 mg of glimepiride and 2000 mg of MET. After 12-weektreatment, glimepiride plus MET combination showed improvement in metabolic control as assessed by changes in HbA1c, FPG, and post prandial glucose (PPG). Primary efficacy parameter, HbA1c, was significantly reduced to (7.65 ± 1.70) at the end of the treatment from the baseline value (8.35 ± 0.93) (P < 0.001). Of the patients, 65.79% showed ≥0.5% reduction in HbA1c and or HbA1c <7% at the end of the therapy. FPG and PPG were significantly reduced at the end of the therapy as compared with baseline values (P < 0.001). Moreover, the lipid profile was also improved during the treatment period. The addition of glimepiride to MET is an effective treatment for patients inadequately controlled on sulfonylurea or Met alone. A combination of glimepiride with MET achieves good glycemic control with better tolerability profile. |
| | |
Authors:
|
Anil Pareek; Nitin B Chandurkar; Harsha R Salkar; Mangala S Borkar; Dharmendra Tiwari |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-2-15 |
Journal Detail:
|
Title: American journal of therapeutics Volume: - ISSN: 1536-3686 ISO Abbreviation: - Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-2-17 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9441347 Medline TA: Am J Ther Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
1Medical Affairs and Clinical Research, Ipca Laboratories Limited, Kandivli (West), Mumbai, India; 2Clinical Research and Development, Ipca Laboratories Limited, Kandivli (West), Mumbai, India; 3Department of Medicine, Government Medical College and Hospital, Nagpur, India; 4Department of Medicine, Government Medical College and Hospital, Aurangabad, India; and 5Department of Medicine, GR Medical College and Hospital and J. A. Group of Hospitals, Gwalior, India. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A National Cancer Clinical Trials Network: Recommendations From the Institute of Medicine.
Next Document: Clinical Overview of Fibromyalgia.